We are live on ! Find out more
AGN

Allergan Inc
AGN

Delisted

AGN was delisted on the 16th of March, 2015.

709 hedge funds and large institutions have $29.2B invested in Allergan Inc in 2013 Q4 according to their latest regulatory filings, with 118 funds opening new positions, 239 increasing their positions, 245 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more funds holding in top 10

Funds holding in top 10: 1129 (+18)

162% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 45

14% more capital invested

Capital invested by funds: $25.6B → $29.2B (+$3.65B)

13% more call options, than puts

Call options by funds: $387M | Put options by funds: $344M

10% more funds holding

Funds holding: 642709 (+67)

2% less repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 245

Holders
709
Holders Change
+67
Holders Change %
+10.44%
% of All Funds
20.57%
Holding in Top 10
29
Holding in Top 10 Change
+18
Holding in Top 10 Change %
+163.64%
% of All Funds
0.84%
New
118
Increased
239
Reduced
245
Closed
45
Calls
$387M
Puts
$344M
Net Calls
+$43.6M
Net Calls Change
+$76.8M

AGN Hedge Fund Activity: Q4 2013 in Review

709 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Allergan Inc (AGN) for Q4 2013, worth a combined $29.2B — up 14% from $25.6B a quarter earlier.

Buyers outnumbered sellers: 118 funds opened new AGN positions and 45 closed out — a net gain of 73 holders — while 239 added to existing stakes and 245 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $260M. The largest seller was Sands Capital Management, exiting entirely with an estimated $671M sold.

  • 709 institutional investors held Allergan Inc (AGN) as of Q4 2013, up from 642 in Q3 2013.
  • Funds reported $29.2B of Allergan Inc stock for Q4 2013, up 14% quarter-over-quarter.
  • 118 funds opened new Allergan Inc positions in Q4 2013 and 45 closed out, a net change of +73 holders.
  • The largest Allergan Inc buyer in Q4 2013 was T. Rowe Price Associates, an estimated $260M added.
  • The largest Allergan Inc seller in Q4 2013 was Sands Capital Management, an estimated $671M sold.

Based on aggregated 13F filings for Q4 2013.